Deal round-up 11/05

East Hill, Softbank and Bure feature.

East Hill invests in ThromboGenics

East Hill Advisors has invested a first round of $12.8m in ThromboGenics.

The Dublin-based biotech firm focuses on the treatment of cardiovascular disease.

ThromboGenics plans to put the money into R&D.

The company, valued at $82.8 million, has appointed Landon Clay and Jeffrey Garner of East Hill to its board.

Softbank goes for Theworkx

Softbank Europe Ventures and Episode 1 Partners have co-led a £3m investment in Theworkx.net.

Newbury-based Theworkx is developing a sales database of small and medium-sized enterprises. It said the money would be used to launch its services in Autumn.

Richard Tahta of Episode 1 and Sean Fee of Softbank joined the board of directors.

Theworkx.net said it may try to raise new money towards the end of the year.

Bure buys Framfab’s technology

Swedish VC Bure has acquired Framfab Technology for $1.7m from troubled IT consultancy Framtidsfabriken.

Framtidsfabriken has said it will run out of money by June if it does not raise significant capital.